TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31915060

Group type: EXPERIMENTAL
Intervention: Media Aware, a web-based comprehensive sexual health promotion program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard health education programming (delayed intervention group)
Number of subjects: 0
Study: 29615092

Group type: EXPERIMENTAL
Intervention: Group-based metacognitive therapy plus usual cardiac rehabilitation
Number of subjects: 332

Group type: COMPARATOR
Intervention: Usual cardiac rehabilitation alone
Number of subjects: 332
Study: 28830536

Group type: EXPERIMENTAL
Intervention: 12-week bounding exercise programme (BEP) consisting of functional plyometric exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular soccer training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 12-week bounding exercise programme (BEP)
Number of subjects: 0
Study: 25275411

Group type: EXPERIMENTAL
Intervention: Preservative-free fixed dose combination of tafluprost 0.0015% and timolol 0.5%
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Preservative-free non-fixed combination of tafluprost 0.0015% and timolol 0.5%
Number of subjects: 28
Study: 24066341

Group type: EXPERIMENTAL
Intervention: Composite graft (rhBMP-2/ACS, CCFDAB, PRP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 100% autogenous graft
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Composite graft
Number of subjects: 20

Group type: COMPARATOR
Intervention: Autogenous graft
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both grafts
Number of subjects: 20
Study: 21946361

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX) 20 mg for 8 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 18713545

Group type: EXPERIMENTAL
Intervention: Laser therapy in addition to traditional therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Laser therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (normal skin)
Number of subjects: 60
Study: 17030764

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12757076

Group type: EXPERIMENTAL
Intervention: 1 drain inserted at the axilla area (Group I)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2 conventional drains inserted into the pectoral area and axilla area (Group II)
Number of subjects: 60
Study: 9989194

Group type: EXPERIMENTAL
Intervention: Nicotine patches (21 mg/day)
Number of subjects: 522

Group type: COMPARATOR
Intervention: Nicotine patches (14 mg/day)
Number of subjects: 522

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 522
Study: 8524578

Group type: EXPERIMENTAL
Intervention: Thymoxamine HCl 0.5%
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pilocarpine HCl 1%
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pilocarpine HCl 2%
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no miotic employed)
Number of subjects: 12
Study: 2152664

Group type: EXPERIMENTAL
Intervention: Iron-supplemented milk (15 mg elementary iron as ferrous sulphate and 100 mg ascorbic acid per 100 g powder)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (same milk with no supplement)
Number of subjects: 86
Study: 575490

Group type: EXPERIMENTAL
Intervention: 1020 mg creatinol O-phosphate (group A)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 2040 mg creatinol O-phosphate (group B)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 3060 mg creatinol O-phosphate (group C)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo (group D)
Number of subjects: 4
Study: 30799646

Group type: EXPERIMENTAL
Intervention: Targeted therapy (TT)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Immuno-oncology (IO)
Number of subjects: 440
Study: 28183326

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (IIV3) administered at day 1 and day 180
Number of subjects: 200

Group type: COMPARATOR
Intervention: Tetanus‐diphtheria‐pertussis vaccine administered at day 180
Number of subjects: 200
Study: 26615504

Group type: EXPERIMENTAL
Intervention: Crestal implants (group A)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Subcrestal implants (group B)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 23
Study: 24472518

Group type: EXPERIMENTAL
Intervention: Pregabalin (150-600mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NPSI questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QST
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hierarchical cluster analysis
Number of subjects: 0
Study: 22038939

Group type: EXPERIMENTAL
Intervention: Tolterodine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 20658249

Group type: COMPARATOR
Intervention: Heat stress alone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combined heat stress and exercise
Number of subjects: 8
Study: 17670997

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 208
Study: 16299118

Group type: EXPERIMENTAL
Intervention: Nocturnal NIV
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group without ventilatory support
Number of subjects: 48
Study: 11750964

Group type: EXPERIMENTAL
Intervention: Progesterone prophylaxis after amniocentesis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 0
Study: 9865559

Group type: EXPERIMENTAL
Intervention: Dual sphincterotomy (group I, n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pancreatic sphincterotomy alone (group II, n = 30)
Number of subjects: 60
Study: 7882873

Group type: EXPERIMENTAL
Intervention: Passages (modified therapeutic community methods)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Standard methadone maintenance therapy (comparison group)
Number of subjects: 327
Study: 31797190

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 90
Study: 30132224

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of terlipressin (Group A)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Intravenous boluses of terlipressin (Group B)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Continuous infusion of terlipressin
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: MELD-Na score
Number of subjects: 86
Study: 28791734

Group type: EXPERIMENTAL
Intervention: Acute alcohol dose at 0.4 or 0.6 g/kg
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Heavy drinkers
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Light drinkers
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 96
Study: 26271327

Group type: EXPERIMENTAL
Intervention: Genetic risk score (GRS) disclosure
Number of subjects: 220

Group type: COMPARATOR
Intervention: Conventional risk score (CRS) disclosure
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Psychosocial measures
Number of subjects: 220
Study: 24056196

Group type: EXPERIMENTAL
Intervention: PD patients OFF medication
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: PD patients ON medication
Number of subjects: 21

Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 21
Study: 21726949

Group type: EXPERIMENTAL
Intervention: Skin stretching (SS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scar excision without additional techniques (SE)
Number of subjects: 0
Study: 19800611

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 20
Study: 17086500

Group type: EXPERIMENTAL
Intervention: Proximity-sensing chair with auditory feedback
Number of subjects: 20

Group type: COMPARATOR
Intervention: Without auditory feedback device
Number of subjects: 20
Study: 15623196

Group type: EXPERIMENTAL
Intervention: 2.0-cm wide cuff
Number of subjects: 17

Group type: COMPARATOR
Intervention: 2.5-cm wide cuff
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Patients with diabetes
Number of subjects: 17

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 17
Study: 11239189

Group type: EXPERIMENTAL
Intervention: Psychological therapy (specific details not provided)
Number of subjects: 448
Study: 8976244

Group type: EXPERIMENTAL
Intervention: Self‐reinforced polyglycolic acid spiral stent
Number of subjects: 72

Group type: COMPARATOR
Intervention: Suprapubic catheter
Number of subjects: 72

Group type: COMPARATOR
Intervention: Indwelling catheter
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 72
Study: 7965649

Group type: EXPERIMENTAL
Intervention: Combination therapy (specific agents not detailed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zidovudine monotherapy
Number of subjects: 0
Study: 3119687

Group type: EXPERIMENTAL
Intervention: Renografin‐76
Number of subjects: 816

Group type: COMPARATOR
Intervention: Angiovist‐370
Number of subjects: 816
Study: 29324972

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab
Number of subjects: 413

Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 413
Study: 27529771

Group type: EXPERIMENTAL
Intervention: 1.9-g/d n-3 PUFA treatment
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 24632963

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 200

Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 200
Study: 23338733

Group type: EXPERIMENTAL
Intervention: Intra-articular lidocaine injection
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no analgesia)
Number of subjects: 42
Study: 21126390

Group type: EXPERIMENTAL
Intervention: Spironolactone (1 mg/kg per day) for 7 days
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (no additional intervention)
Number of subjects: 68
Study: 18791910

Group type: EXPERIMENTAL
Intervention: Arthroscopic resection
Number of subjects: 25

Group type: COMPARATOR
Intervention: Open excision
Number of subjects: 25
Study: 15905731

Group type: EXPERIMENTAL
Intervention: Antiretrovirals (ARVs)
Number of subjects: 8451

Group type: EXPERIMENTAL
Intervention: Single, dual, and triple nucleoside reverse transcriptase inhibitors (NRTIs)
Number of subjects: 8451

Group type: EXPERIMENTAL
Intervention: Didanosine (ddI)
Number of subjects: 8451

Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) with hydroxyurea (HU)
Number of subjects: 8451

Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) with stavudine (d4T)
Number of subjects: 8451

Group type: EXPERIMENTAL
Intervention: Indinavir (IDV)/didanosine (ddI)/stavudine (d4T) with or without hydroxyurea (HU)
Number of subjects: 8451
Study: 12894613

Group type: EXPERIMENTAL
Intervention: Consenting group (CG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonconsenting group (NG)
Number of subjects: 0
Study: 10589441

Group type: EXPERIMENTAL
Intervention: Maté (Ilex paraguariensis) extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other commercially available plant preparations
Number of subjects: 0
Study: 8947991

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 4
Study: 1931471

Group type: EXPERIMENTAL
Intervention: ALO1567 (100 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ALO1567 (200 mg daily)
Number of subjects: 0
Study: 6809421

Group type: EXPERIMENTAL
Intervention: Intracervical levonorgestrel‐releasing mini‐T device
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intrauterine levonorgestrel device
Number of subjects: 100

Group type: COMPARATOR
Intervention: Copper‐T‐200 (Cu‐T‐200)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both levonorgestrel devices
Number of subjects: 100
Study: 31081693

Group type: EXPERIMENTAL
Intervention: GLP‐1RA (specific drugs include liraglutide, exenatide, and lixisenatide)
Number of subjects: 4242

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 4242

Group type: COMPARATOR
Intervention: Exenatide
Number of subjects: 4242

Group type: COMPARATOR
Intervention: Lixisenatide
Number of subjects: 4242
Study: 28278333

Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg daily for 1 year)
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: Sorafenib (800 mg daily for 1 year)
Number of subjects: 1069

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1069
Study: 26245724

Group type: EXPERIMENTAL
Intervention: Listening to music (water and wave sounds)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no music intervention)
Number of subjects: 37
Study: 24461877

Group type: EXPERIMENTAL
Intervention: 2.4 g amino acids/(kg·d) plus 2-3 g lipid/(kg·d)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 3.6 g amino acids/(kg·d) plus 2-3 g lipid/(kg·d)
Number of subjects: 28

Group type: COMPARATOR
Intervention: 2.4 g amino acids/(kg·d) (control group)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Increasing energy intake from 40 to 60 kcal/(kg·d)
Number of subjects: 28
Study: 22542332

Group type: COMPARATOR
Intervention: Continuous Wave (CW) CO(2) laser (5 W)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Char-Free (CF) CO(2) laser (140 Hz, 400 μs, 33 mJ)
Number of subjects: 60
Study: 19593180

Group type: EXPERIMENTAL
Intervention: Venlafaxine (VEN) administered at daily dosages ranging from 75 to 150 mg.
Number of subjects: 28
Study: 17478166

Group type: EXPERIMENTAL
Intervention: 3D echocardiography using > or = 6 component 2D image planes
Number of subjects: 25

Group type: COMPARATOR
Intervention: Biplane 2D echocardiography
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 3D echocardiography using 4, 6, 8, 10, and 20 component 2D planes
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 3D echocardiography
Number of subjects: 25
Study: 15516884

Group type: EXPERIMENTAL
Intervention: Ketamine (0.7 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tramadol (15 mg/kg)
Number of subjects: 40
Study: 11505244

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Model of Everyday Memory intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9760804

Group type: EXPERIMENTAL
Intervention: LATP test with ECG, ECHO, and SPECT
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: LATP test with SPECT
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: LATP test with ECHO
Number of subjects: 55

Group type: COMPARATOR
Intervention: LATP test with ExT
Number of subjects: 55
Study: 8155446

Group type: EXPERIMENTAL
Intervention: Desflurane with low-dose (10 micrograms kg‐1) fentanyl
Number of subjects: 51

Group type: COMPARATOR
Intervention: Fentanyl (high-dose 50 micrograms kg‐1) with midazolam
Number of subjects: 51
Study: 3412292

Group type: EXPERIMENTAL
Intervention: Intranasal pine extract (0.15 cc by metered dose spray, starting at 1/100,000 w/v, followed by 1/10,000, 1/1000 and 1/100 at 20 minute intervals)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Positive skin test (ST) to pine pollen extract
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 8-tree mixture
Number of subjects: 100

Group type: COMPARATOR
Intervention: Skin testing with pine pollen extract, 8-tree mixture, histamine and negative control
Number of subjects: 100
Study: 31822016

Group type: EXPERIMENTAL
Intervention: Metabolically Healthy Overweight/Obese Children (MHO)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Moderate-to-Vigorous Physical Activity (MVPA)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Cardiorespiratory Fitness (CRF)
Number of subjects: 188
Study: 31064896

Group type: EXPERIMENTAL
Intervention: Indigenous Ready‐to‐use Therapeutic Food (Medical Nutrition Therapy)
Number of subjects: 1105

Group type: COMPARATOR
Intervention: Standard Nutrition Therapy
Number of subjects: 1105
Study: 28433887

Group type: EXPERIMENTAL
Intervention: Clay Art Therapy (CAT)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Visual Art (VA)
Number of subjects: 106
Study: 26385052

Group type: EXPERIMENTAL
Intervention: L-arginine (6.4 g/day for 18 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23622086

Group type: EXPERIMENTAL
Intervention: ICU admissions from 1988 to 2012
Number of subjects: 482601

Group type: EXPERIMENTAL
Intervention: Patients with chronic obstructive pulmonary disease, seizures, surgery for aortic dissection and subarachnoid hemorrhage
Number of subjects: 482601

Group type: EXPERIMENTAL
Intervention: Six diagnoses (not specified)
Number of subjects: 482601

Group type: EXPERIMENTAL
Intervention: Seven diagnoses (not specified)
Number of subjects: 482601

Group type: EXPERIMENTAL
Intervention: ICU admissions from 2001 to 2012
Number of subjects: 482601
Study: 21559279

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) administration within three hours of injury
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Cost of administering TXA
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Incremental cost of giving TXA versus not giving TXA
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Estimated incremental cost per LY gained of administering TXA
Number of subjects: 1000
Study: 19327910

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) to the head and neck
Number of subjects: 15
Study: 17573455

Group type: EXPERIMENTAL
Intervention: Hematopoietics (for anemia)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychostimulants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: l-carnitine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: modafinil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: bupropion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs) such as paroxetine
Number of subjects: 0
Study: 15010082

Group type: COMPARATOR
Intervention: Placebo-Bedrest
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Testosterone-T3
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Alendronate-T3
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: T3 plus bedrest
Number of subjects: 82
Study: 11213869

Group type: EXPERIMENTAL
Intervention: Meal plan permitting up to 10% of total energy as added sugars or sweets (S)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional meal plan (no concentrated sweets) (C)
Number of subjects: 48
Study: 9846910

Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg at 8-h intervals for 5 days)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 8635830

Group type: EXPERIMENTAL
Intervention: 200 mg ferrous sulphate (FeSO4) tablet per day for 15 weeks
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: FeSO4 tablets along with 2,000,000 IU of vitamin A as single dose
Number of subjects: 81

Group type: COMPARATOR
Intervention: No supplements (Control)
Number of subjects: 81
Study: 2469747

Group type: EXPERIMENTAL
Intervention: organo-heparinoid cream (Hirudoid)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo cream
Number of subjects: 12
Study: 908448

Group type: EXPERIMENTAL
Intervention: Tantalum clips
Number of subjects: 110

Group type: COMPARATOR
Intervention: Conventional vasectomy (control)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both groups (Tantalum clips and Conventional vasectomy)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Recanalization methods after clip removal
Number of subjects: 110
Study: 31535922

Group type: EXPERIMENTAL
Intervention: Great Village
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Great Village + exercise
Number of subjects: 142

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 142
Study: 31195099

Group type: EXPERIMENTAL
Intervention: Zumba exercise for 60 minutes twice weekly for 8 weeks
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group with no intervention
Number of subjects: 98
Study: 27628624

Group type: EXPERIMENTAL
Intervention: Oral Hygiene Care Program (OHCP) administered twice a week for six sessions during in-hospital rehabilitation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 62
Study: 26306996

Group type: EXPERIMENTAL
Intervention: Rapid molecular testing for Staphylococcus aureus
Number of subjects: 252

Group type: COMPARATOR
Intervention: Standard of care culture-based testing
Number of subjects: 252
Study: 25120809

Group type: EXPERIMENTAL
Intervention: S-1 monotherapy
Number of subjects: 41
Study: 21718522

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B with sodium stibogluconate (SSG)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B with miltefosine
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Miltefosine alone
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 189
Study: 19237977

Group type: EXPERIMENTAL
Intervention: Mini-cardiopulmonary bypass systems
Number of subjects: 0
Study: 17713342

Group type: EXPERIMENTAL
Intervention: 20% sucrose solution
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water (negative control)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 10% glucose + 10% fructose (active control)
Number of subjects: 12
Study: 15562367

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg weekly
Number of subjects: 41

Group type: COMPARATOR
Intervention: No alendronate (control)
Number of subjects: 41
Study: 11673772

Group type: EXPERIMENTAL
Intervention: Mixed diet (M; 15% protein, 30% fat, 55% carbohydrate)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High-fat diet (HF; 15% protein, 60% fat, 25% carbohydrate)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (HC; 15% protein, 15% fat, 70% carbohydrate)
Number of subjects: 11
Study: 9728732

Group type: EXPERIMENTAL
Intervention: Schizophrenic patients
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 77
Study: 7983123

Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty in severely deformed knees (varus or valgus deformity > 20 degrees)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (alignment within 5 degrees of normal)
Number of subjects: 51
Study: 2714570

Group type: EXPERIMENTAL
Intervention: Hypnosis with instruction to imagine eating delicious meals
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Hypnosis with instruction for deep relaxation
Number of subjects: 2

Group type: COMPARATOR
Intervention: No hypnosis
Number of subjects: 2
Study: 772478

Group type: EXPERIMENTAL
Intervention: Feprazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benzydamine
Number of subjects: 0